Effect of gender on treatment outcomes in type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 102, Issue 3, 2013, Pages 167-174

  McGill, J B ^a   Vlajnic, A ^b   Knutsen, P G ^a   Recklein, C ^a   Rimler, M ^c   Fisher, S J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANOFI   (France)

^c Medpace ^*  (United States)

Author keywords

Gender; Glycemic control; Hypoglycemia; Insulin glargine; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; PREMIXED INSULIN; UNCLASSIFIED DRUG;

ARTICLE; DIABETIC DIET; DISEASE SEVERITY; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN;

GENDER; GLYCEMIC CONTROL; HYPOGLYCEMIA; INSULIN GLARGINE; TYPE 2 DIABETES MELLITUS;

ADULT; BLOOD GLUCOSE; BODY WEIGHT; CLINICAL TRIALS, PHASE III AS TOPIC; CLINICAL TRIALS, PHASE IV AS TOPIC; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX FACTORS; TREATMENT OUTCOME;

EID: 84889585954     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2013.10.001     Document Type: Article

References (33)

1. Regitz-Zagrosek V., Lehmkuhl E., Mahmoodzadeh S. Gender aspects of the role of the metabolic syndrome as a risk factor for cardiovascular disease. Gend Med 2007, 4(Suppl. B):S162.
2. Geer E.B., Shen W. Gender differences in insulin resistance, body composition, and energy balance. Gend Med 2009, 6(Suppl. 1):60-75.
3. Faerch K., Borch-Johnsen K., Vaag A., Jørgensen T., Witte D.R. Sex differences in glucose levels: a consequence of physiology or methodological convenience? The Inter99 study. Diabetologia 2010, 53:858-865.
4. Nuutila P., Knuuti M.J., Mäki M., Laine H., Ruotsalainen U., Teräs M., et al. Gender and insulin sensitivity in the heart and in skeletal muscles. Studies using positron emission tomography. Diabetes 1995, 44:31-36.
5. Flanagan D.E., Holt R.I., Owens P.C., Cockington R.J., Moore V.M., Robinson J.S., et al. Gender differences in the insulin-like growth factor axis response to a glucose load. Acta Physiol (Oxf) 2006, 187:371-378.
6. Flanagan D.E., Vaile J.C., Petley G.W., Phillips D.I., Godsland I.F., Owens P., et al. Gender differences in the relationship between leptin, insulin resistance and the autonomic nervous system. Regul Pept 2007, 140:37-42.
7. Perreault L., Ma Y., Dagogo-Jack S., Horton E., Marrero D., Crandall J., et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care 2008, 31:1416-1421.
8. Laws A., Hoen H.M., Selby J.V., Saad M.F., Haffner S.M., Howard B.V. Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status Relation to plasma triglyceride and apolipoprotein B concentrations. Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Arterioscler Thromb Vasc Biol 1997, 17:64-71.
9. Shalev V., Chodick G., Heymann A.D., Kokia E. Gender differences in healthcare utilization and medical indicators among patients with diabetes. Public Health 2005, 119:45-49.
10. Tang Y.H., Pang S.M., Chan M.F., Yeung G.S., Yeung V.T. Health literacy, complication awareness, and diabetic control in patients with type 2 diabetes mellitus. J Adv Nurs 2008, 62:74-83.
11. Chiu C.J., Wray L.A. Gender differences in functional limitations in adults living with type 2 diabetes: biobehavioral and psychosocial mediators. Ann Behav Med 2011, 41:71-82.
12. Nilsson P.M., Theobald H., Journath G., Fritz T. Gender differences in risk factor control and treatment profile in diabetes: a study in 229 Swedish primary health care centres. Scand J Prim Health Care 2004, 22:27-31.
13. Wexler D.J., Grant R.W., Meigs J.B., Nathan D.M., Cagliero E. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 2005, 28:514-520.
14. Cryer P.E. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 2002, 45:937-948.
15. Amiel S.A., Maran A., Powrie J.K., Umpleby A.M., Macdonald I.A. Gender differences in counterregulation to hypoglycaemia. Diabetologia 1993, 36:460-464.
16. Davis S.N., Cherrington A.D., Goldstein R.E., Jacobs J., Price L. Effects of insulin on the counterregulatory response to equivalent hypoglycemia in normal females. Am J Physiol 1993, 265(5 Pt 1):E680-E689.
17. Diamond M.P., Jones T., Caprio S., Hallarman L., Diamond M.C., Addabbo M., et al. Gender influences counterregulatory hormone responses to hypoglycemia. Metabolism 1993, 42:1568-1572.
18. Gerstein H.C., Yale J.F., Harris S.B., Issa M., Stewart J.A., Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006, 23:736-742.
19. Riddle M.C., Rosenstock J., Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003, 26:3080-3086. Insulin glargine 4002 study investigators.
20. Rosenstock J., Sugimoto D., Strange P., Stewart J.A., Soltes-Rak E., Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006, 29:554-559.
21. Meneghini L.F., Traylor L., Schwartz S.L. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus. Endocr Pract 2010, 16:588-589.
22. NCT01336751 Lantus versus Humalog mix as add-on therapy in type diabetes patients failing sulfonylurea and metformin combination treatment 2012, Available at http://clinicaltrials.gov/ct2/show/NCT01336751 [accessed 03.09.12].
23. Janka H.U., Plewe G., Riddle M.C., Kliebe-Frisch C., Schweitzer M.A., Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005, 28:254-259.
24. Bretzel R.G., Nuber U., Landgraf W., Owens D.R., Bradley C., Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008, 371:1073-1084.
25. Blicklé J-F., Hancu N., Piletic M., Profozic V., Shestakova M., Dain M.P., et al. Insulin glargine provides greater improvements in glycaemic control vs intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1C levels; the TULIP study. Diabetes Obes Metab 2009, 11:379-386.
26. Yki-Järvinen H., Kauppinen-Mäkelin R., Tiikkainen M., Vähätalo M., Virtamo H., Nikkilä K., et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006, 49:442-451.
27. Glasgow R.E., McCaul K.D., Schafer L.C. Barriers to regimen adherence among persons with insulin-dependent diabetes. J Behav Med 1986, 9:65-77.
28. Walker E.A., Molitch M., Kramer M.K., Kahn S., Ma Y., Edelstein S., et al. Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program. Diabetes Care 2006, 29:1997-2002.
29. Frier B.M. How hypoglycaemia can affect the life of a person with diabetes. Diabetes Metab Res Rev 2008, 24:87-92.
30. Cox D.J., Irvine A., Gonder-Frederick L., Nowacek G., Butterfield J. Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care 1987, 10:617-621.
31. Wild D., von Maltzahn R., Brohan E., Christensen T., Clauson P., Gonder-Frederick L. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns 2007, 68:10-15.
32. Anderbro T., Amsberg S., Adamson U., Bolinder J., Lins P.E., Wredling R., et al. Fear of hypoglycaemia in adults with Type 1 diabetes. Diabet Med 2010, 27:1151-1158.
33. Garg S.K., Paul J.M., Karsten J.I., Menditto L., Gottlieb P.A. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes. Diabetes Technol Ther 2004, 6:589-595.